CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Indego Exoskeletondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03082898
NCT03082898N/ACompleted
CompareCT.gov

Mobility and Therapeutic Benefits Resulting From Exoskeleton Use in a Clinical Setting (SC140121 Study 1 and 2)

Vanderbilt University·interventional·Posted Mar 17, 2017·Updated Feb 16, 2022

In Brief

A clinical study evaluating Indego Exoskeleton for Spinal Cord Injury. Completed, enrolled 41 participants across 3 sites.

Detailed Summary

The proposed study is intended to inform the hypotheses that (1) regular dosing of exoskeleton walking will provide health benefits to non-ambulatory and poorly-ambulatory individuals with SCI, including decreased pain and spasticity, improvements in bowel and bladder function, decreased body-mass index (BMI), enhanced well-being; (2) regular dosing of exoskeleton walking will facilitate neurological or functional recovery in some individuals with SCI, particularly those with incomplete injuries; and (3) the level of mobility enabled by a lower limb exoskeleton is commensurate with the walking speeds, distances, and surfaces required for community ambulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 17, 2017
Enrollment StartNov 15, 2016
Primary CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.3 years ago

Interventions

Indego Exoskeletondevice

Regular dosing of Indego Exoskeleton walking.